Literatur

NVL Prävention und Therapie von Netzhautkomplikationen bei Diabetes

2. Auflage, 2015. Version 2 – Druckversion (PDF ) | Kapitelübersicht | weitere Informationen

1. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Typ-2-Diabetes. Präventions und Therapie von Netzhautkomplikationen - Langfassung, 1. Auflage. Version 2.6. 2006 [cited: 2016 Jul 27]. Available from: http://www.leitlinien.de/mdb/downloads/nvl/diabetes-mellitus/archiv/netzhautkomplikationen/dm-netzhautkomplikationen-vers2.6-lang.pdf

2. Europarat, Verbindung der Schweizer Ärztinnen und Ärzte, Ärztliche Zentralstelle Qualitätssicherung (ÄZQ), et al. Entwicklung einer Methodik für die Ausarbeitung von Leitlinien für optimale medizinische Praxis. Empfehlung Rec (2001)13 des Europarates am 10. Oktober 2001 und Erläuterndes Memorandum. Deutschsprachige Ausgabe. Z Arztl Fortbild Qualitatssich 2002;96(Suppl III):3-60 http://www.leitlinien.de/mdb/edocs/pdf/literatur/europaratmethdt.pdf.

3. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV). Beurteilungskriterien für Leitlinien in der medizinischen Versorgung - Beschlüsse der Vorstände der Bundesärztekammer und Kassenärztlicher Bundesvereinigung, Juni 1997. Dtsch Arztebl 1997;94(33):A-2154-5.

4. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), Ärztliche Zentralstelle Qualitätssicherung (ÄZQ). Das Leitlinien-Manual von AWMF und ÄZQ. Entwicklung und Implementierung von Leitlinien in der Medizin. Z Arztl Fortbild Qualitatssich 2001;95(Suppl I):4-84.

5. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Das AWMF-Regelwerk Leitlinien. München: Zuckschwerdt; 2012 Available from: http://www.awmf.org/leitlinien/awmf-regelwerk.html.

6. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV). Das Leitlinien-Clearingverfahren von Bundesärztekammer und Kassenärztlicher Bundesvereinigung in Zusammenarbeit mit der Deutschen Krankenhausgesellschaft und den Spitzenverbänden der Gesetzlichen Krankenversicherungen, Ziele und Arbeitsplan. Dtsch Arztebl 1999;96(33):A-2105-6.

7. Ärztliches Zentrum für Qualität in der Medizin (ÄZQ). Das Deutsche Leitlinien-Clearingverfahren 1999-2005. Hintergrund, Zielsetzung, Ergebnisse. Abschlussbericht. Leitlinien-Clearingverfahren von Bundesärztekammer und Kassenärztlicher Bundesvereinigung in Kooperation mit Deutscher Krankenhausgesellschaft, Spitzenverbände der Krankenversicherungen und Gesetzlicher Rentenversicherung. Norderstedt: BoD, Books on Demand; 2006 (äzq Schriftenreihe; 24). Available from: http://www.leitlinien.de/leitlinienmethodik/clearingverfahren.

8. Ärztliches Zentrum für Qualität in der Medizin (ÄZQ), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Deutsches Instrument zur methodischen Leitlinien-Bewertung (DELBI). Fassung 2005/2006. Z Arztl Fortbild Qualitatssich 2005;99(8):468-519.

9. Ärztliches Zentrum für Qualität in der Medizin (ÄZQ), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Deutsches Instrument zur methodischen Leitlinien-Bewertung (DELBI). Fassung 2005/2006 + Domäne 8. 2008 [cited: 2016 Jan 04]. Available from: http://www.leitlinien.de/mdb/edocs/pdf/literatur/delbi-fassung-2005-2006-domaene-8-2008.pdf

10. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationales Programm für VersorgungsLeitlinien. Methoden-Report 4. Auflage. 2010 [cited: 2015 Sep 15]. Available from: http://www.leitlinien.de/mdb/downloads/nvl/methodik/mr-aufl-4-version-1.pdf, DOI: 10.6101/AZQ/000061

11. Bundesärztekammer (BÄK), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), Kassenärztliche Bundesvereinigung (KBV). Nationale VersorgungsLeitlinie Prävention und Therapie von Netzhautkomplikationen bei Diabetes - Leitlinien-Report, 2. Auflage. Version 2. 2015 [cited: 2015 Nov 18]. Available from: http://doi.org/10.6101/AZQ/000263, DOI: 10.6101/AZQ/000263

12. Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ 2001;323(7308):334-6 http://www.ncbi.nlm.nih.gov/pubmed/11498496.

13. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ 2004;328(7454):1490-7 http://www.ncbi.nlm.nih.gov/pubmed/15205295.

14. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6 http://www.ncbi.nlm.nih.gov/pubmed/18436948.

15. Dunham RB. Nominal Group Technique: A Users' guide. Madison: Wisconsin School of Business; 1998.

16. Stinner B, Bauhofer A, Sitter H, et al. Nominaler Gruppenprozess als Konsensusinstrument zur Einschränkung der Therapieheterogenität in einer komplexen "outcome"-Studie. Intensivmed Notfallmed 2000;37 Suppl. 2:30.

17. Murphy MK, Black NA, Lamping DL, et al. Consensus development methods, and their use in clinical guideline development. Health Technol Assess 1998;2(3):i-88 http://www.ncbi.nlm.nih.gov/pubmed/9561895.

18. Hirneiss C, Neubauer AS, Tribus C, et al. "Value-based medicine" in der Augenheilkunde. Ophthalmologe 2006;103(6):493-500 http://www.ncbi.nlm.nih.gov/pubmed/16763866, DOI: 10.1007/s00347-006-1340-9.

19. Deutsche Ophthalmologische Gesellschaft (DOG), Pfeiffer N, Knauer C, et al. Weißbuch zur Situation der ophthalmologischen Forschung in Deutschland. München: DOG; 2008 Available from: http://www.dog.org/wp-content/uploads/2009/12/DOG_Weissbuch_2008.pdf.

20. Brown MM, Brown GC, Sharma S, et al. Quality of life with visual acuity loss from diabetic retinopathy and age-related macular degeneration. Arch Ophthalmol 2002;120(4):481-4 http://www.ncbi.nlm.nih.gov/pubmed/11934322.

21. Fenwick EK, Xie J, Pesudovs K, et al. Assessing disutility associated with diabetic retinopathy, diabetic macular oedema and associated visual impairment using the Vision and Quality of Life Index. Clin Exp Optom 2012;95(3):362-70 http://www.ncbi.nlm.nih.gov/pubmed/22537275, DOI: 10.1111/j.1444-0938.2012.00742.x.

22. Hirai FE, Tielsch JM, Klein BE, et al. Ten-year change in vision-related quality of life in type 1 diabetes: Wisconsin epidemiologic study of diabetic retinopathy. Ophthalmology 2011;118(2):353-8 http://www.ncbi.nlm.nih.gov/pubmed/20884058, DOI: 10.1016/j.ophtha.2010.06.022.

23. Nordrheinische Gemeinsame Einrichtung Disease-Management-Programme, Hagen B, Altenhofen L, et al. Qualitätssicherungsbericht 2013. Disease-Management-Programme in Nordrhein. Brustkrebs, Diabetes mellitus Typ 1/Typ 2, Koronare Herzkrankheit, Asthma/COPD. Düsseldorf: Nordrheinische Gemeinsame Einrichtung DMP; 2014 Available from: http://www.kvno.de/downloads/quali/qualbe_dmp13.pdf.

24. Icks A, Rathmann W, Haastert B, et al. Versorgungsqualität und Ausmass von Komplikationen an einer bevölkerungsbezogenen Stichprobe von Typ 2-Diabetespatienten. Der KORA-Survey 2000. Dtsch Med Wochenschr 2006;131(3):73-8 http://www.ncbi.nlm.nih.gov/pubmed/16418944.

25. Heller T, Blum M, Spraul M, et al. Folgeerkrankungen des Diabetes mellitus: Prävalenzen in der Bundesrepublik Deutschland. Dtsch Med Wochenschr 2014;139(15):786-91 http://www.ncbi.nlm.nih.gov/pubmed/24691694, DOI: 10.1055/s-0034-1369889 [doi].

26. Hammes HP, Kerner W, Hofer S, et al. Diabetic retinopathy in type 1 diabetes-a contemporary analysis of 8,784 patients. Diabetologia 2011;54(8):1977-84 http://www.ncbi.nlm.nih.gov/pubmed/21638132, DOI: 10.1007/s00125-011-2198-1.

27. Scottish Intercollegiate Guidelines Network (SIGN). Management of diabetes. A national clinical guideline. Edinburgh: SIGN; 2010 (SIGN Publications; 116). Available from: http://www.sign.ac.uk/pdf/sign116.pdf.

28. Hesse L, Grusser M, Hoffstadt K, et al. Populationsbezogene Erhebung zur diabetischen Retinopathie in Wolfsburg. Ophthalmologe 2001;98(11):1065-8 http://www.ncbi.nlm.nih.gov/pubmed/11729738.

29. Blum M, Kloos C, Müller N, et al. Prävalenz der diabetischen Retinopathie. Ophthalmologe 2007;104(6):499-4 http://www.ncbi.nlm.nih.gov/pubmed/17457588.

30. Diabetes-Patienten-Verlaufsdokumentation (DPV), Kompetenznetz Diabetes mellitus, Hammes HP, et al. Risk Factors for Retinopathy and DME in Type 2 Diabetes-Results from the German/Austrian DPV Database1. PLoS One 2015;10(7):e0132492 http://www.ncbi.nlm.nih.gov/pubmed/26177037, DOI: 10.1371/journal.pone.0132492.

31. Huppertz E, Pieper L, Klotsche J, et al. Diabetes Mellitus in German Primary Care: quality of glycaemic control and subpopulations not well controlled - results of the DETECT study. Exp Clin Endocrinol Diabetes 2009;117(1):6-14 http://www.ncbi.nlm.nih.gov/pubmed/18465681, DOI: 10.1055/s-2008-1073127.

32. Böhler S, Pittrow D, Pieper L, et al. Diabetes mellitus in der primärärztlichen Versorgung: Häufigkeit von mikro- und makrovaskulären Komplikationen – Ergebnisse der DETECT Studie. 41. Jahrestagung der Deutschen Diabetes-Gesellschaft. Diabet Stoffw 2006;1(S1):1-A315, DOI: 10.1055/s-2006-944040.

33. Raum P, Lamparter J, Ponto KA, et al. Prevalence and Cardiovascular Associations of Diabetic Retinopathy and Maculopathy: Results from the Gutenberg Health Study1. PLoS One 2015;10(6):e0127188 http://www.ncbi.nlm.nih.gov/pubmed/26075604, DOI: 10.1371/journal.pone.0127188.

34. Kloos C, Müller N, Wolf G, et al. Better HbA1c and blood pressure control in patients with diabetes mellitus treated at a primary health care level 10 years after initiation of a diabetes quality improvement program. Exp Clin Endocrinol Diabetes 2011;119(8):459-62 http://www.ncbi.nlm.nih.gov/pubmed/21472663, DOI: 10.1055/s-0031-1273746.

35. Nordrheinische Gemeinsame Einrichtung Disease-Management-Programme. Qualitätssicherungsbericht 2007. Disease Management Programme in Nordrhein. Brustkrebs, Diabetes mellitus Typ 1 / Typ 2, Koronare Herzkrankheit, Asthma / COPD. Düsseldorf: Nordrheinische Gemeinsame Einrichtung DMP; 2008 Available from: http://www.kvno.de/downloads/quali/qualbe_dmp07.pdf.

36. Looker HC, Nyangoma SO, Cromie DT, et al. Rates of referable eye disease in the Scottish National Diabetic Retinopathy Screening Programme. Br J Ophthalmol 2014;98(6):790-5 http://www.ncbi.nlm.nih.gov/pubmed/24599419, DOI: 10.1136/bjophthalmol-2013-303948.

37. Ruta LM, Magliano DJ, Lemesurier R, et al. Prevalence of diabetic retinopathy in Type 2 diabetes in developing and developed countries. Diabet Med 2013;30(4):387-98 http://www.ncbi.nlm.nih.gov/pubmed/23331210, DOI: 10.1111/dme.12119.

38. Claessen H, Genz J, Bertram B, et al. Evidence for a considerable decrease in total and cause-specific incidences of blindness in Germany. Eur J Epidemiol 2012;27(7):519-24 http://www.ncbi.nlm.nih.gov/pubmed/22711586, DOI: 10.1007/s10654-012-9705-7.

39. Finger RP, Bertram B, Wolfram C, et al. Blindheit und Sehbehinderung in Deutschland. Leichter Rückgang der Prävalenz. Dtsch Arztebl 2012;109(27-28):484-9 http://www.ncbi.nlm.nih.gov/pubmed/22833762, DOI: 10.3238/arztebl.2012.0484.

40. Finger RP, Fimmers R, Holz FG, et al. Prevalence and causes of registered blindness in the largest federal state of Germany. Br J Ophthalmol 2011;95(8):1061-7 http://www.ncbi.nlm.nih.gov/pubmed/21378005, DOI: 10.1136/bjo.2010.194712.

41. Finger RP, Fimmers R, Holz FG, et al. Incidence of blindness and severe visual impairment in Germany: projections for 2030. Invest Ophthalmol Vis Sci 2011;52(7):4381-9 http://www.ncbi.nlm.nih.gov/pubmed/21447690, DOI: 10.1167/iovs.10-6987.

42. Genz J, Scheer M, Trautner C, et al. Reduced incidence of blindness in relation to diabetes mellitus in southern Germany? Diabet Med 2010;27(10):1138-43 http://www.ncbi.nlm.nih.gov/pubmed/20854381, DOI: 10.1111/j.1464-5491.2010.03081.x.

43. Bertram B, Gante C, Hilgers RD. Zunahme der Untersuchungen wegen Katarakt, Glaukom, diabetischer Retinopathie und Makuladegeneration. Ophthalmologe 2013;111(8):757-64 http://www.ncbi.nlm.nih.gov/pubmed/24343245, DOI: 10.1007/s00347-013-2966-z.

44. Linder R, Horenkamp-Sonntag D, Engel S, et al. Validität der ärztlichen Dokumentation von Disease Management Programmen. Dtsch Med Wochenschr 2014;139(1-2):19-22 http://www.ncbi.nlm.nih.gov/pubmed/24062021, DOI: 10.1055/s-0033-1349545.

45. Lampert T, Kroll LE, von der LE, et al. Sozioökonomischer Status und Gesundheit. Ergebnisse der Studie zur Gesundheit Erwachsener in Deutschland (DEGS1). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2013;56(5-6):814-21 http://www.ncbi.nlm.nih.gov/pubmed/23703503, DOI: 10.1007/s00103-013-1695-4.

46. Prokofyeva E, Wegener A, Zrenner E. Cataract prevalence and prevention in Europe: a literature review. Acta Ophthalmol 2013;91(5):395-405 http://www.ncbi.nlm.nih.gov/pubmed/22715900, DOI: 10.1111/j.1755-3768.2012.02444.x.

47. Fullerton B, Jeitler K, Seitz M, et al. Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus. Cochrane Database Syst Rev 2014;2:CD009122 http://www.ncbi.nlm.nih.gov/pubmed/24526393, DOI: 10.1002/14651858.CD009122.pub2.

48. Gibbons CH, Freeman R. Treatment-induced neuropathy of diabetes: an acute, iatrogenic complication of diabetes. Brain 2015;138(Pt 1):43-52 http://www.ncbi.nlm.nih.gov/pubmed/25392197, DOI: 10.1093/brain/awu307.

49. Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012;35(3):556-64 http://www.ncbi.nlm.nih.gov/pubmed/22301125, DOI: 10.2337/dc11-1909.

50. Bundesärztekammer (BÄK), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), Kassenärztliche Bundesvereinigung (KBV). Nationale VersorgungsLeitlinie Therapie des Typ-2-Diabetes - Langfassung, 1. Auflage. Version 4. 2014 [cited: 2016 Jul 27]. Available from: http://doi.org/10.6101/AZQ/000213, DOI: 10.6101/AZQ/000213

51. Bundesärztekammer (BÄK), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), Kassenärztliche Bundesvereinigung (KBV). Nationale VersorgungsLeitlinie Nierenerkrankungen bei Diabetes im Erwachsenenalter - Langfassung, 1. Auflage, Version 6. 2010 [cited: 2016 Jul 27]. Available from: http://doi.org/10.6101/AZQ/000248, DOI: 10.6101/AZQ/000248

52. Girach A, Vignati L. Diabetic microvascular complications--can the presence of one predict the development of another? J Diabetes Complications 2006;20(4):228-37 http://www.ncbi.nlm.nih.gov/pubmed/16798474, DOI: 10.1016/j.jdiacomp.2006.03.001.

53. DCCT Research Group. Effect of pregnancy on microvascular complications in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Diabetes Care 2000;23(8):1084-91 http://www.ncbi.nlm.nih.gov/pubmed/10937502.

54. Kaaja R, Loukovaara S. Progression of retinopathy in type 1 diabetic women during pregnancy. Curr Diabetes Rev 2007;3(2):85-93 http://www.ncbi.nlm.nih.gov/pubmed/18220659.

55. Rasmussen KL, Laugesen CS, Ringholm L, et al. Progression of diabetic retinopathy during pregnancy in women with type 2 diabetes. Diabetologia 2010;53(6):1076-83 http://www.ncbi.nlm.nih.gov/pubmed/20225131, DOI: 10.1007/s00125-010-1697-9.

56. Lachin JM, Genuth S, Nathan DM, et al. Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial--revisited. Diabetes 2008;57(4):995-1001 http://www.ncbi.nlm.nih.gov/pubmed/18223010.

57. Klein R, Moss SE, Klein BE, et al. The Wisconsin epidemiologic study of diabetic retinopathy. XI. The incidence of macular edema. Ophthalmology 1989;96(10):1501-10 http://www.ncbi.nlm.nih.gov/pubmed/2587045.

58. Klein R, Klein BE, Moss SE, et al. Ten-year incidence of gross proteinuria in people with diabetes. Diabetes 1995;44(8):916-23 http://www.ncbi.nlm.nih.gov/pubmed/7621997.

59. Agarwal R, Debella YT, Giduma HD, et al. Long-term retinal, renal and cardiovascular outcomes in diabetic chronic kidney disease without proteinuria. Nephrol Dial Transplant 2012;27(1):310-7 http://www.ncbi.nlm.nih.gov/pubmed/21669884, DOI: 10.1093/ndt/gfr320.

60. Knudsen ST, Bek T, Poulsen PL, et al. Macular edema reflects generalized vascular hyperpermeability in type 2 diabetic patients with retinopathy. Diabetes Care 2002;25(12):2328-34 http://www.ncbi.nlm.nih.gov/pubmed/12453981.

61. Kramer CK, Retnakaran R. Concordance of retinopathy and nephropathy over time in Type 1 diabetes: an analysis of data from the Diabetes Control and Complications Trial. Diabet Med 2013;30(11):1333-41 http://www.ncbi.nlm.nih.gov/pubmed/23909911, DOI: 10.1111/dme.12296.

62. Song SH, Hardisty CA. Early onset type 2 diabetes mellitus: a harbinger for complications in later years--clinical observation from a secondary care cohort. QJM 2009;102(11):799-806 http://www.ncbi.nlm.nih.gov/pubmed/19734298, DOI: 10.1093/qjmed/hcp121.

63. Thomas RL, Dunstan F, Luzio SD, et al. Incidence of diabetic retinopathy in people with type 2 diabetes mellitus attending the Diabetic Retinopathy Screening Service for Wales: retrospective analysis. BMJ 2012;344:e874 http://www.ncbi.nlm.nih.gov/pubmed/22362115, DOI: 10.1136/bmj.e87.

64. Wong J, Molyneaux L, Constantino M, et al. Timing is everything: age of onset influences long-term retinopathy risk in type 2 diabetes, independent of traditional risk factors. Diabetes Care 2008;31(10):1985-90 http://www.ncbi.nlm.nih.gov/pubmed/18628565, DOI: 10.2337/dc08-0580.

65. Song SH, Gray TA. Early-onset type 2 diabetes: high risk for premature diabetic retinopathy. Diabetes Res Clin Pract 2011;94(2):207-11 http://www.ncbi.nlm.nih.gov/pubmed/21855159, DOI: 10.1016/j.diabres.2011.07.030.

66. Best RM, Chakravarthy U. Diabetic retinopathy in pregnancy. Br J Ophthalmol 1997;81(3):249-51 http://www.ncbi.nlm.nih.gov/pubmed/9135391.

67. Chan WC, Lim LT, Quinn MJ, et al. Management and outcome of sight-threatening diabetic retinopathy in pregnancy. Eye 2004;18(8):826-32 http://www.ncbi.nlm.nih.gov/pubmed/14976547, DOI: 10.1038/sj.eye.6701340.

68. Deutsche Diabetes Gesellschaft (DDG), Kleinwechter H, Bührer C, et al. S3-Leitlinie Diabetes und Schwangerschaft. Evidenzbasierte Leitlinie der Deutschen Diabetes-Gesellschaft. 2014 [cited: 2015 Mar 19]. Available from: http://www.awmf.org/uploads/tx_szleitlinien/057-023l_S3_Diabetes_und_Schwangerschaft_2014-12.pdf

69. Das R, Kerr R, Chakravarthy U, et al. Dyslipidemia and Diabetic Macular Edema: A Systematic Review and Meta-Analysis. Ophthalmology 2015;122(9):1820-7 http://www.ncbi.nlm.nih.gov/pubmed/26150053, DOI: 10.1016/j.ophtha.2015.05.011.

70. Sacks FM, Hermans MP, Fioretto P, et al. Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case-control study in 13 countries. Circulation 2014;129(9):999-1008 http://www.ncbi.nlm.nih.gov/pubmed/24352521, DOI: 10.1161/CIRCULATIONAHA.113.002529.

71. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN), Deutsche Gesellschaft für Suchtforschung und Suchttherapie (DG-Sucht), et al. S3-Leitlinie "Screening, Diagnostik und Behandlung des schädlichen und abhängigen Tabakkonsums". AWMF-Register Nr. 076-006. (Stand: 09.02.2015). 2014 [cited: 2015 Jun 17]. Available from: http://www.awmf.org/uploads/tx_szleitlinien/076-006l_S3_Tabak_2015-02.pdf

72. Kramer CK, Rodrigues TC, Canani LH, et al. Diabetic retinopathy predicts all-cause mortality and cardiovascular events in both type 1 and 2 diabetes: meta-analysis of observational studies. Diabetes Care 2011;34(5):1238-44 http://www.ncbi.nlm.nih.gov/pubmed/21525504, DOI: 10.2337/dc11-0079.

73. Aiello LP, Gardner TW, King GL, et al. Diabetic retinopathy. Diabetes Care 1998;21(1):143-56 http://www.ncbi.nlm.nih.gov/pubmed/9538986.

74. DCCT Research Group. Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial (DCCT 1998). Arch Ophthalmol 1998;116(7):874-86 http://www.ncbi.nlm.nih.gov/pubmed/9682700.

75. Silva PS, Cavallerano JD, Haddad NM, et al. Peripheral Lesions Identified on Ultrawide Field Imaging Predict Increased Risk of Diabetic Retinopathy Progression over 4 Years. Ophthalmology 2015;122(5):949-56 http://www.ncbi.nlm.nih.gov/pubmed/25704318, DOI: 10.1016/j.ophtha.2015.01.008.

76. Early Treatment Diabetic Retinopathy Study Research Group (ETDRS). Focal photocoagulation treatment of diabetic macular edema. Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS report no. 19. Early Treatment Diabetic Retinopathy Study Research Group. Arch Ophthalmol 1995;113(9):1144-55 http://www.ncbi.nlm.nih.gov/pubmed/7661748.

77. Virgili G, Menchini F, Casazza G, et al. Optical coherence tomography (OCT) for detection of macular oedema in patients with diabetic retinopathy. Cochrane Database Syst Rev 2015;1:CD008081 http://www.ncbi.nlm.nih.gov/pubmed/25564068, DOI: 10.1002/14651858.CD008081.pub3.

78. Virgili G, Parravano M, Menchini F, et al. Anti-vascular endothelial growth factor for diabetic macular oedema. Cochrane Database Syst Rev 2014;(10):CD007419 http://www.ncbi.nlm.nih.gov/pubmed/25342124, DOI: 10.1002/14651858.CD007419.pub4.

79. Browning DJ, Scott AQ, Peterson CB, et al. The risk of missing angle neovascularization by omitting screening gonioscopy in acute central retinal vein occlusion. Ophthalmology 1998;105(5):776-84 http://www.ncbi.nlm.nih.gov/pubmed/9593375, DOI: 10.1016/S0161-6420(98)95014-X.

80. McDonald HR, Williams GA, Scott IU, et al. Laser scanning imaging for macular disease: a report by the American Academy of Ophthalmology. Ophthalmology 2007;114(6):1221-8 http://www.ncbi.nlm.nih.gov/pubmed/17466377, DOI: 10.1016/j.ophtha.2007.03.035.

81. Folgar FA, Jaffe GJ, Ying GS, et al. Comparison of Optical Coherence Tomography Assessments in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology 2014;121(10):1956-65 http://www.ncbi.nlm.nih.gov/pubmed/24835760, DOI: 10.1016/j.ophtha.2014.04.020.

82. Do DV, Cho M, Nguyen QD, et al. The impact of optical coherence tomography on surgical decision making in epiretinal membrane and vitreomacular traction. Trans Am Ophthalmol Soc 2006;104:161-6 http://www.ncbi.nlm.nih.gov/pubmed/17471336.

83. Kaiser PK, Riemann CD, Sears JE, et al. Macular traction detachment and diabetic macular edema associated with posterior hyaloidal traction. Am J Ophthalmol 2001;131(1):44-9 http://www.ncbi.nlm.nih.gov/pubmed/11162978.

84. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011;118(4):615-25 http://www.ncbi.nlm.nih.gov/pubmed/21459215, DOI: 10.1016/j.ophtha.2011.01.031.

85. RISE and RIDE Research Group, Nguyen QD, Brown DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012;119(4):789-801 http://www.ncbi.nlm.nih.gov/pubmed/22330964, DOI: 10.1016/j.ophtha.2011.12.039.

86. da Vinci Study Group, Do DV, Nguyen QD, et al. One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology 2012;119(8):1658-65 http://www.ncbi.nlm.nih.gov/pubmed/22537617, DOI: 10.1016/j.ophtha.2012.02.010.

87. Rajendram R, Fraser-Bell S, Kaines A, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol 2012;130(8):972-9 http://www.ncbi.nlm.nih.gov/pubmed/22491395, DOI: 10.1001/archophthalmol.2012.393.

88. Guigou S, Hajjar C, Parrat E, et al. Étude rétrospective du traitement par Ozurdex® dans l'œdème maculaire diabétique : MOZART study. J Fr Ophtalmol 2014;37(6):480-5 http://www.ncbi.nlm.nih.gov/pubmed/24813119, DOI: 10.1016/j.jfo.2014.03.001.

89. Boyer DS, Yoon YH, Belfort R, Jr., et al. Three-Year, Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Diabetic Macular Edema. Ophthalmology 2014;121(10):1904-14 http://www.ncbi.nlm.nih.gov/pubmed/24907062, DOI: 10.1016/j.ophtha.2014.04.024.

90. Deutsche Diabetes Gesellschaft (DDG), Böhm BO, Dreyer M, et al. S3-Leitlinie Therapie des Diabetes mellitus Typ 1. Langfassung. 2011 [cited: 2015 Mar 30]. Available from: http://www.awmf.org/uploads/tx_szleitlinien/057-013l_S3_Therapie_des_Typ_1_Diabetes_2012-03.pdf

91. Echouffo-Tcheugui JB, Ali MK, Roglic G, et al. Screening intervals for diabetic retinopathy and incidence of visual loss: a systematic review. Diabet Med 2013;30(11):1272-92 http://www.ncbi.nlm.nih.gov/pubmed/23819487, DOI: 10.1111/dme.12274.

92. Taylor-Phillips S, Mistry H, Leslie R, et al. Extending the diabetic retinopathy screening interval beyond 1 year: systematic review. Br J Ophthalmol 2016;100(1):105-14 http://www.ncbi.nlm.nih.gov/pubmed/25586713, DOI: 10.1136/bjophthalmol-2014-305938.

93. American Diabetes Association (ADA). Standards of medical care in diabetes 2014. Diabetes Care 2014;37 Suppl 1:S14-S80 http://www.ncbi.nlm.nih.gov/pubmed/24357209, DOI: 10.2337/dc14-S014.

94. Canadian Diabetes Association (CDA), Advani A, Altomare F, et al. Retinopathy - Clinical Practice Guidelines 2013. Can J Diabetes 2013;37 Suppl 1:S137-S141 http://www.ncbi.nlm.nih.gov/pubmed/24070936, DOI: 10.1016/j.jcjd.2013.01.038.

95. Canadian Ophthalmological Society, Hooper P, Cruess A, et al. Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of diabetic retinopathy. Can J Ophthalmol 2012;47(2 Suppl):S1-54 http://www.ncbi.nlm.nih.gov/pubmed/22632804, DOI: 10.1016/j.jcjo.2011.12.025.

96. Ministry of Health, Malaysia (MYDoH). Screening of Diabetic Retinopathy. 2011 [cited: 2014 Jul 17]. Available from: http://www.moh.gov.my/attachments/6601.pdf

97. National Institute for Clinical Excellence (NICE). Type 2 Diabetes. National clinical guideline for management in primary and secondary care (update). London: Royal College Of Physicians; 2008 Available from: http://www.nice.org.uk/nicemedia/live/11983/40803/40803.pdf.

98. Veterans Health Administration and Department of Defense (VADoD). VADoD Clinical Practice Guideline for the Management of Diabetes Mellitus. Version 4.0. 2010 [cited: 2014 Jul 17]. Available from: http://www.healthquality.va.gov/guidelines/CD/diabetes/DM2010_FUL-v4e.pdf

99. Ryden L, Grant PJ, Anker SD, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013;34(39):3035-87 http://www.ncbi.nlm.nih.gov/pubmed/23996285, DOI: 10.1093/eurheartj/eht108.

100. Leese GP, Stratton IM, Land M, et al. Progression of diabetes retinal status within community screening programs and potential implications for screening intervals. Diabetes Care 2015;38(3):488-94 http://www.ncbi.nlm.nih.gov/pubmed/25524948, DOI: 10.2337/dc14-1778.

101. Porta M, Maurino M, Severini S, et al. Clinical characteristics influence screening intervals for diabetic retinopathy. Diabetologia 2013;56(10):2147-52 http://www.ncbi.nlm.nih.gov/pubmed/23827966, DOI: 10.1007/s00125-013-2989-7.

102. Aspelund T, Thornorisdottir O, Olafsdottir E, et al. Individual risk assessment and information technology to optimise screening frequency for diabetic retinopathy. Diabetologia 2011;54(10):2525-32 http://www.ncbi.nlm.nih.gov/pubmed/21792613.

103. Mehlsen J, Erlandsen M, Poulsen PL, et al. Individualized optimization of the screening interval for diabetic retinopathy: a new model. Acta Ophthalmol 2012;90(2):109-14 http://www.ncbi.nlm.nih.gov/pubmed/20384605, DOI: 10.1111/j.1755-3768.2010.01882.x.

104. van der Heijden AA, Walraven I, van 't RE, et al. Validation of a model to estimate personalised screening frequency to monitor diabetic retinopathy. Diabetologia 2014;57(7):1332-8 http://www.ncbi.nlm.nih.gov/pubmed/24763851, DOI: 10.1007/s00125-014-3246-4.

105. Soto-Pedre E, Pinies JA, Hernaez-Ortega MC. External validation of a risk assessment model to adjust the frequency of eye-screening visits in patients with diabetes mellitus. J Diabetes Complications 2015;29(4):508-11 http://www.ncbi.nlm.nih.gov/pubmed/25725582, DOI: 10.1016/j.jdiacomp.2014.12.020.

106. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352(9131):837-53 http://www.ncbi.nlm.nih.gov/pubmed/9742976.

107. Hemmingsen B, Lund SS, Gluud C, et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev 2013;11:CD008143 http://www.ncbi.nlm.nih.gov/pubmed/24214280, DOI: 10.1002/14651858.CD008143.pub3.

108. DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group (DCCT 1993). N Engl J Med 1993;329(14):977-86 http://www.ncbi.nlm.nih.gov/pubmed/8366922.

109. Do DV, Wang X, Vedula SS, et al. Blood pressure control for diabetic retinopathy. Cochrane Database Syst Rev 2015;1:CD006127 http://www.ncbi.nlm.nih.gov/pubmed/25637717, DOI: 10.1002/14651858.CD006127.pub2.

110. Bergerhoff K, Clar C, Richter B. Aspirin in diabetic retinopathy. A systematic review. Endocrinol Metab Clin North Am 2002;31(3):779-93 http://www.ncbi.nlm.nih.gov/pubmed/12227131.

111. Chew EY, Klein ML, Murphy RP, et al. Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report no. 20. Arch Ophthalmol 1995;113(1):52-5 http://www.ncbi.nlm.nih.gov/pubmed/7826294.

112. Early Treatment Diabetic Retinopathy Study Research Group (ETDRS). Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Ophthalmology 1991;98(5 Suppl):757-65 http://www.ncbi.nlm.nih.gov/pubmed/2062511.

113. Aiello LP, Cahill MT, Wong JS. Systemic considerations in the management of diabetic retinopathy. Am J Ophthalmol 2001;132(5):760-76 http://www.ncbi.nlm.nih.gov/pubmed/11704039, DOI: 10.1016/S0002-9394(01)01124-2.

114. Ryan A, Saad T, Kirwan C, et al. Maintenance of perioperative antiplatelet and anticoagulant therapy for vitreoretinal surgery. Clin Experiment Ophthalmol 2013;41(4):387-95 http://www.ncbi.nlm.nih.gov/pubmed/23094982, DOI: 10.1111/ceo.12017.

115. Brown JS, Mahmoud TH. Anticoagulation and clinically significant postoperative vitreous hemorrhage in diabetic vitrectomy. Retina 2011;31(10):1983-7 http://www.ncbi.nlm.nih.gov/pubmed/21836531, DOI: 10.1097/IAE.0b013e31821800cd.

116. Eikelboom JW, Hirsh J, Spencer FA, et al. Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e89S-119S http://www.ncbi.nlm.nih.gov/pubmed/22315278, DOI: 10.1378/chest.11-2293.

117. Silva PS, Cavallerano JD, Sun JK, et al. Effect of systemic medications on onset and progression of diabetic retinopathy. Nat Rev Endocrinol 2010;6(9):494-508 http://www.ncbi.nlm.nih.gov/pubmed/20664533, DOI: 10.1038/nrendo.2010.122.

118. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366(9497):1607-21 http://www.ncbi.nlm.nih.gov/pubmed/16271642.

119. Evans JR, Michelessi M, Virgili G. Laser photocoagulation for proliferative diabetic retinopathy. Cochrane Database Syst Rev 2014;11:CD011234 http://www.ncbi.nlm.nih.gov/pubmed/25420029, DOI: 10.1002/14651858.CD011234.pub2.

120. Early Treatment Diabetic Retinopathy Study Research Group (ETDRS). Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991;98(5 Suppl):766-85 http://www.ncbi.nlm.nih.gov/pubmed/2062512.

121. Oh JH, Kim SW, Kwon SS, et al. The change of macular thickness following single-session pattern scan laser panretinal photocoagulation for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2015;253(1):57-63 http://www.ncbi.nlm.nih.gov/pubmed/24862300, DOI: 10.1007/s00417-014-2663-x.

122. Soman M, Ganekal S, Nair U, et al. Effect of panretinal photocoagulation on macular morphology and thickness in eyes with proliferative diabetic retinopathy without clinically significant macular edema. Clin Ophthalmol 2012;6:2013-7 http://www.ncbi.nlm.nih.gov/pubmed/23271879, DOI: 10.2147/OPTH.S37340.

123. Lee SB, Yun YJ, Kim SH, et al. Changes in macular thickness after panretinal photocoagulation in patients with severe diabetic retinopathy and no macular edema. Retina 2010;30(5):756-60 http://www.ncbi.nlm.nih.gov/pubmed/20453801, DOI: 10.1097/IAE.0b013e3181c701e0.

124. Ferris FL, III, Podgor MJ, Davis MD. Macular edema in Diabetic Retinopathy Study patients. Diabetic Retinopathy Study Report Number 12. Ophthalmology 1987;94(7):754-60 http://www.ncbi.nlm.nih.gov/pubmed/3658347.

125. UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317(7160):703-13 http://www.ncbi.nlm.nih.gov/pubmed/9732337.

126. Ferris F. Early photocoagulation in patients with either type I or type II diabetes. Trans Am Ophthalmol Soc 1996;94:505-37 http://www.ncbi.nlm.nih.gov/pubmed/8981711.

127. Diabetic Retinopathy Vitrectomy Study Research Group. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Four-year results of a randomized trial: Diabetic Retinopathy Vitrectomy Study Report 5. Arch Ophthalmol 1990;108(7):958-64 http://www.ncbi.nlm.nih.gov/pubmed/2196036.

128. Helbig H, Kellner U, Bornfeld N, et al. Vitrektomie bei diabetischer Retinopathie: Ergebnisse, Risikofaktoren, Komplikationen. Klin Monatsbl Augenheilkd 1998;212(5):339-42 http://www.ncbi.nlm.nih.gov/pubmed/9677573.

129. Ostri C. Intraocular surgery in a large diabetes patient population: risk factors and surgical results. Acta Ophthalmol 2014;92(Suppl Thesis 1):1-13 http://www.ncbi.nlm.nih.gov/pubmed/24809766, DOI: 10.1111/aos.12364.

130. American Academy of Ophthalmology (AAO). Glossary-Eintrag: CSME. 2015 [cited: 2015 Aug 28]. Available from: http://www.aao.org/preferred-practice-pattern/diabetic-retinopathy-ppp--2014#GLOSSARY

131. Early Treatment Diabetic Retinopathy Study Research Group (ETDRS). Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1987;94(7):761-74 http://www.ncbi.nlm.nih.gov/pubmed/3658348.

132. Early Treatment Diabetic Retinopathy Study Research Group (ETDRS). Techniques for scatter and local photocoagulation treatment of diabetic retinopathy: Early Treatment Diabetic Retinopathy Study Report no. 3. The Early Treatment Diabetic Retinopathy Study Research Group. Int Ophthalmol Clin 1987;27(4):254-64 http://www.ncbi.nlm.nih.gov/pubmed/3692707.

133. Mohamed QA, Ross A, Chu CJ. Diabetic retinopathy (treatment). BMJ Clin Evid 2011;2011:0702 http://www.ncbi.nlm.nih.gov/pubmed/21609511.

134. Fong DS, Strauber SF, Aiello LP, et al. Comparison of the modified Early Treatment Diabetic Retinopathy Study and mild macular grid laser photocoagulation strategies for diabetic macular edema. Arch Ophthalmol 2007;125(4):469-80 http://www.ncbi.nlm.nih.gov/pubmed/17420366, DOI: 10.1001/archopht.125.4.469.

135. American Academy of Ophthalmology (AAO). Preferred practice pattern: diabetic retinopathy. 2014 [cited: 2014 Nov 03]. Available from: http://one.aao.org/preferred-practice-pattern/diabetic-retinopathy-ppp--2014

136. Ford JA, Lois N, Royle P, et al. Current treatments in diabetic macular oedema: systematic review and meta-analysis. BMJ Open 2013;3(3):e002269 http://www.ncbi.nlm.nih.gov/pubmed/23457327, DOI: 10.1136/bmjopen-2012-002269.

137. Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal Aflibercept for Diabetic Macular Edema. Ophthalmology 2014;121(11):2247-54 http://www.ncbi.nlm.nih.gov/pubmed/25012934, DOI: 10.1016/j.ophtha.2014.05.006.

138. Diabetic Retinopathy Clinical Research Network, Elman MJ, Bressler NM, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011;118(4):609-14 http://www.ncbi.nlm.nih.gov/pubmed/21459214, DOI: 10.1016/j.ophtha.2010.12.033.

139. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008;115(9):1447-59.e10 http://www.ncbi.nlm.nih.gov/pubmed/18662829, DOI: 10.1016/j.ophtha.2008.06.015.

140. Elman MJ, Ayala A, Bressler NM, et al. Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt versus Deferred Laser Treatment: 5-Year Randomized Trial Results. Ophthalmology 2014;122(2):375-81 http://www.ncbi.nlm.nih.gov/pubmed/25439614, DOI: 10.1016/j.ophtha.2014.08.047.

141. Bhavsar AR, Sandler DR, Gentile RC. Intravitreal injections, antibiotics and endophthalmitis. Eye (Lond) 2013;27(12):1426-7 http://www.ncbi.nlm.nih.gov/pubmed/24136574, DOI: 10.1038/eye.2013.225.

142. Bhavsar AR, Stockdale CR, Ferris FL, III, et al. Update on risk of endophthalmitis after intravitreal drug injections and potential impact of elimination of topical antibiotics. Arch Ophthalmol 2012;130(6):809-10 http://www.ncbi.nlm.nih.gov/pubmed/22801859, DOI: 10.1001/archophthalmol.2012.227.

143. Jager RD, Aiello LP, Patel SC, et al. Risks of intravitreous injection: a comprehensive review. Retina 2004;24(5):676-98 http://www.ncbi.nlm.nih.gov/pubmed/15492621.

144. Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010;33(11):2399-405 http://www.ncbi.nlm.nih.gov/pubmed/20980427, DOI: 10.2337/dc10-0493.

145. Cheung CS, Wong AW, Lui A, et al. Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections. Ophthalmology 2012;119(8):1609-14 http://www.ncbi.nlm.nih.gov/pubmed/22480743, DOI: 10.1016/j.ophtha.2012.02.014.

146. European Medicines Agency (EMA). Zusammenfassung der Merkmale des Arzneimittels "Eylea 40 mg/ml Injektionslösung in einer Fertigspritze". Last updated: 20/04/2015. 2012 [cited: 2015 Jun 02]. Available from: http://www.ema.europa.eu/docs/de_DE/document_library/EPAR_-_Product_Information/human/002392/WC500135815.pdf

147. European Medicines Agency (EMA). Zusammenfassung der Merkmale des Arzneimittels "Lucentis 10 mg/ml Injektionslösung". Last updated: 30/10/2014. 2008 [cited: 2015 Jun 02]. Available from: http://www.ema.europa.eu/docs/de_DE/document_library/EPAR_-_Product_Information/human/000715/WC500043546.pdf

148. Diabetic Retinopathy Clinical Research Network (DRCRnet). Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. N Engl J Med 2015;372(13):1193-203 http://www.ncbi.nlm.nih.gov/pubmed/25692915, DOI: 10.1056/NEJMoa1414264.

149. World Health Organization (WHO). WHO Model List of Essential Medicines. 18th list. 2013 [cited: 2015 May 29]. Available from: http://www.who.int/iris/bitstream/10665/93142/1/EML_18_eng.pdf?ua=1

150. VEGF-Hemmer (I): Therapie des diabetischen Makulaödems. Arznei-Telegramm 2015;46(8):73-7.

151. Grover D, Li TJ, Chong CC. Intravitreal steroids for macular edema in diabetes. Cochrane Database Syst Rev 2008;(1):CD005656 http://www.ncbi.nlm.nih.gov/pubmed/18254088, DOI: 10.1002/14651858.CD005656.pub2.

152. Campochiaro PA, Brown DM, Pearson A, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology 2012;119(10):2125-32 http://www.ncbi.nlm.nih.gov/pubmed/22727177, DOI: 10.1016/j.ophtha.2012.04.030.

153. Alimera Sciences. ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg For Intravitreal Injection. Initial U.S. Approval: 1963. Revised: 12/2014. 2014 [cited: 2015 Aug 28]. Available from: http://www.alimerasciences.com/wp-content/uploads/2014/09/iluvien-prescribing-information.pdf

154. European Medicines Agency (EMA). Zusammenfassung der Merkmale des Arzneimittels "OZURDEX 700 Mikrogramm intravitreales Implantat in einem Applikator". Last updated: 07/05/2015. 2013 [cited: 2015 May 29]. Available from: http://www.ema.europa.eu/docs/de_DE/document_library/EPAR_-_Product_Information/human/001140/WC500095499.pdf

155. Alimera Sciences Limited. Zusammenfassung der Merkmale des Arzneimittels "ILUVIEN 190 Mikrogramm intravitreales Implantat im Applikator". Stand der Information: 12/2013. 2013 [cited: 2015 May 29]. Available from: http://portal.dimdi.de/amispb/doc/2014/02/03/2182809/OBFMF45BC79501CF1323.pdf

156. Cunha-Vaz J, Ashton P, Iezzi R, et al. Sustained Delivery Fluocinolone Acetonide Vitreous Implants: Long-Term Benefit in Patients with Chronic Diabetic Macular Edema. Ophthalmology 2014;121(10):1892-903 http://www.ncbi.nlm.nih.gov/pubmed/24935282, DOI: 10.1016/j.ophtha.2014.04.019.

157. Medicines and Healthcare Products Regulatory Agency (MHRA). Iluvien 190 micrograms Intravitreal Implant in Applicator. Public Assessment Report. 2012 [cited: 2015 Sep 08]. Available from: http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con171936.pdf

158. Early Treatment Diabetic Retinopathy Study Research Group (ETDRS). Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol 1985;103(12):1796-806 http://www.ncbi.nlm.nih.gov/pubmed/2866759.

159. Pearce E, Sivaprasad S, Chong NV. Factors affecting reading speed in patients with diabetic macular edema treated with laser photocoagulation. PLoS One 2014;9(9):e105696 http://www.ncbi.nlm.nih.gov/pubmed/25265280, DOI: 10.1371/journal.pone.0105696.

160. Comyn O, Sivaprasad S, Peto T, et al. A randomized trial to assess functional and structural effects of ranibizumab versus laser in diabetic macular edema (the LUCIDATE study). Am J Ophthalmol 2014;157(5):960-70 http://www.ncbi.nlm.nih.gov/pubmed/24531025, DOI: 10.1016/j.ajo.2014.02.019.


Zurück zum Anhang

zuletzt verändert: 15.06.2017 12:35